Wire flash
FinanceBoston Scientific announces global restructuring, expects headcount reductions and ~$500M annual cost savings
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Boston Scientific announced a global restructuring program on July 21, 2026, aimed at driving sustained cost efficiencies and supporting growth. The plan, disclosed in an SEC filing on July 27, includes supply chain optimization, production line transfers, and functional transformation, expected to be largely completed by end of 2029. The medtech giant estimates costs between $700 million and $800 million, with $600-$700 million in future cash outlays, and expects annual pre-tax expense reductions of approximately $500 million. While new jobs will be created, the company anticipates headcount reductions, with up to $300 million allocated for terminations. Boston Scientific's stock rose 2.85% to $45.51 on July 27. The company is set to release Q2 results on July 29, after trimming its full-year outlook by 2% due to competitive dynamics.
Source report
Author: Ross Law Source: Medical Device Network
Boston Scientific is launching a global restructuring program aimed at driving "sustained cost efficiencies" and supporting continued growth, a move the company acknowledges will result in job cuts across the business.
The 2026 restructuring plan includes supply chain optimization, such as transferring certain production lines between facilities, targeted functional transformation, and organizational "structure evolution." Boston stated that these activities are expected to be largely completed by the end of 2029.
Approved by Boston's board on July 21 and disclosed in a Form 8-K filing with the U.S. Securities and Exchange Commission (SEC) on July 27, the medtech giant anticipates the plan will cost between $700 million and $800 million. Of this total:
- Approximately $600 million to $700 million is expected to result in future cash outlays.
- The plan is projected to reduce annual pre-tax expenses by roughly $500 million as benefits are realized.
Market Reaction
Boston's shares on the New York Stock Exchange (NYSE) rose 2.85% to $45.51 at market close on July 27, up from $44.60 at market open. The company has a market capitalization of $67.64 billion. Shares rose an additional 2% at market open on July 28.
Headcount and Cost Breakdown
Boston disclosed that while the plan will create new jobs to support its portfolio and global market needs, it also expects "some" headcount reductions as a result of the restructuring activities. No specific numbers were provided regarding the scale of job cuts.
According to the cost breakdown in Boston's Form 8-K:
- Up to $300 million will be incurred due to terminations.
- Up to $350 million will relate to transferring product manufacturing lines between geographically dispersed facilities.
- Up to $150 million will cover "other" costs associated with completing the plan.
Upcoming Financial Results
Boston is scheduled to release its Q2 results on July 29. In Q1, the company reported revenue of approximately $5.2 billion, broadly in line with the same quarter in 2025. However, Boston trimmed its full-year outlook by 2% at the top end, with CEO Mike Mahoney citing "ongoing competitive dynamics."
This article was originally created and published by Medical Device Network, a GlobalData owned brand.
Source
Yahoo FinanceWestern
Part of this Story
Boston Scientific Announces Global Restructuring, Q2 Results Beat Estimates